Accel Wealth Management Acquires 788 Shares of Bristol-Myers Squibb (NYSE:BMY)

Accel Wealth Management boosted its holdings in Bristol-Myers Squibb (NYSE:BMY) by 19.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,934 shares of the biopharmaceutical company’s stock after acquiring an additional 788 shares during the quarter. Accel Wealth Management’s holdings in Bristol-Myers Squibb were worth $268,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in BMY. Northwest Financial Advisors bought a new stake in Bristol-Myers Squibb during the fourth quarter worth about $27,000. Pacific Capital Wealth Advisors Inc. bought a new stake in Bristol-Myers Squibb during the fourth quarter worth about $34,000. Turtle Creek Wealth Advisors LLC bought a new stake in Bristol-Myers Squibb during the fourth quarter worth about $40,000. Wetzel Investment Advisors Inc. bought a new stake in Bristol-Myers Squibb during the fourth quarter worth about $40,000. Finally, Fairman Group LLC bought a new stake in Bristol-Myers Squibb during the fourth quarter worth about $42,000. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Trading Down 1.0 %

BMY opened at $40.06 on Friday. The firm’s fifty day moving average is $42.37 and its two-hundred day moving average is $47.86. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The firm has a market cap of $81.21 billion, a PE ratio of -12.92, a price-to-earnings-growth ratio of 13.71 and a beta of 0.44. Bristol-Myers Squibb has a twelve month low of $39.63 and a twelve month high of $65.38.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period last year, the business posted $2.05 earnings per share. Equities research analysts anticipate that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be issued a $0.60 dividend. The ex-dividend date is Friday, July 5th. This represents a $2.40 annualized dividend and a yield of 5.99%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Wall Street Analyst Weigh In

Several analysts have weighed in on BMY shares. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Barclays decreased their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. BMO Capital Markets decreased their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th. Finally, Wells Fargo & Company increased their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.